Business Wire

Deutsche Post DHL Group Begins Transition at the Top: Tobias Meyer, P&P Germany Ceo, to Become Group CEO in May 2023

Share

Deutsche Post DHL Group has initiated the leadership transition at the top of the company. The Supervisory Board of Deutsche Post AG has extended Frank Appel’s contract as DPDHL Group CEO until May 4, 2023. His previous contract runs until October 31, 2022. Appel will continue to serve as DPDHL Group CEO until the Annual General Meeting in 2023. Thereafter, Tobias Meyer, will take over as DPDHL Group CEO. Meyer joined the company in 2013 and has held a wide variety of positions including Head of Corporate Development, Chief Operations Officer at DHL Global Forwarding, and Head of Operations and IT at Post & Parcel Germany. He has been CEO of Post & Parcel Germany and a member of the DPDHL Management Board since March 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005516/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tobias Meyer, CEO Post & Parcel Germany (Photo: Business Wire)

“In Tobias Meyer we have a recognized expert of the company taking over as DPDHL Group CEO. He is the ideal choice to continue the very successful path the company has charted. With Strategy 2025, the Management Board successfully executes along the major megatrends of Digitalization, Sustainability, Globalization, and eCommerce“, says Dr. Nikolaus von Bomhard, Chairman of the Supervisory Board of Deutsche Post AG.

Von Bomhard adds: “We thank Frank Appel for his support to assure this seamless transition. Frank Appel’s performance during his more than 13 years at the top of DPDHL Group has been outstanding. He made the company into a leading global logistics powerhouse that connects people and markets, thereby enabling global trade. Under Appel’s leadership, the company has posted one record after the next. Deutsche Post DHL Group has much to thank him for.”

Frank Appel: “After careful consideration, I have decided not to remain for another full term in office. I do this totally convinced that Deutsche Post DHL Group is led by an exceptional management team and supported by highly engaged employees. In Tobias Meyer, we have a top class manager and great colleague to follow as the next DPDHL Group CEO. Under his leadership, Post & Parcel Germany successfully managed the turnaround. I couldn’t have hoped for a better successor.”

As part of a smooth transition, Tobias Meyer will take over the Corporate Function Global Business Services from Frank Appel in July 2022, and hand over his role as CEO Post & Parcel Germany to Nikola Hagleitner, currently Chief Sales Officer at Post & Parcel Germany. Hagleitner has been with the company since 2005 and has worked in three of the five divisions at Deutsche Post DHL Group. With experience across operations, sales and business development, Nikola brings a wealth of expertise to her new position.

In addition, the Supervisory Board has also extended the contract with Oscar de Bok, CEO DHL Supply Chain, for another five years to September 30, 2027.

– End –

Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.

Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.

THE logistics company for the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Monika Schaller
Deutsche Post DHL Group
Head of Group Communications, Sustainability & Brand
Tel.: +49 228 182-9944
E-Mail: pressestelle@dpdhl.com
On the Internet: dpdhl.de/presse
Follow us: twitter.com/DeutschePostDHL

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye